Role of LMO1 in Neuroblastoma Initiation and Maintenance
LMO1 在神经母细胞瘤发生和维持中的作用
基本信息
- 批准号:9452737
- 负责人:
- 金额:$ 60.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced DevelopmentBinding SitesBiological AssayBiological ModelsCell modelCellsCessation of lifeCharacteristicsChildClonal EvolutionComplementDNADNA ResequencingDataDependenceDevelopmentDiseaseDissectionDoxycyclineEnhancersEpigenetic ProcessEventGenesGeneticGenetic DeterminismGenetic Enhancer ElementGenetic PolymorphismGenetic TranscriptionGoalsGrowthHealthHeritabilityHumanInheritedIntronsInvestigationLIM DomainLaboratoriesLeadershipMYCN geneMaintenanceMalignant - descriptorMalignant Childhood NeoplasmMalignant NeoplasmsMediatingMethodsMissionModelingMolecularMolecular TargetMutationNeuroblastomaOncogenesOncogenicOutcomePathway interactionsPenetrancePeripheralPhenotypePredispositionPrincipal InvestigatorProteinsPublic HealthPublishingRecurrenceRegulatory ElementReporterResearchResearch Project GrantsResourcesRoleSingle Nucleotide PolymorphismSiteSomatic MutationSusceptibility GeneSympathetic Nervous SystemTestingTherapeuticTissuesTransgenic OrganismsTreatment FailureUnited States National Institutes of HealthUp-RegulationValidationVariantWorkZebrafishanticancer researchbasecancer genomecancer initiationcell growthchemotherapychildhood cancer mortalityclinically relevantcofactordesignevidence basefunctional genomicsgenetic approachgenetic associationgenome editinggenome wide association studyhigh riskhuman diseasein vivoinduced pluripotent stem cellinnovationinsightmalignant phenotypemolecular subtypesneoplastic cellnervous system developmentneuroblastoma cellnovelnovel therapeuticsoverexpressionpersonalized therapeuticprogramspublic health relevanceself-renewalskillstargeted treatmenttranscription factortumortumor DNAtumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Children with disseminated neuroblastoma have a very high risk of treatment failure and death despite receiving greatly intensified chemotherapy, underscoring the need to design novel molecular therapies for this disease, which constitutes the long-term goal of our proposal. However, recent efforts to discover promising molecular targets in this aggressive pediatric malignancy have revealed a very low somatic mutation rate, and the majority of high-risk tumors do not harbor druggable oncogenic proteins activated by somatic mutations, demonstrating that personalized therapeutic strategies will require insights well beyond those afforded by resequencing tumor DNA alone. This multiple principal investigator project will build on our recent genome- wide association study (GWAS) discovery of a robust genetic association at the LMO1 gene locus, which encodes a LIM-domain-only (LMO) transcriptional cofactor. Together, our published and unpublished preliminary data support a major oncogenic role for LMO1 in the most aggressive subset of neuroblastomas, and suggest the following central hypothesis: LMO1 is required for the initiation and maintenance of the malignant phenotype in a substantial subset of high-risk neuroblastoma cases. We propose to test this original concept in two integrated Specific Aims using the multi-PI leadership mechanism to bring together complementary research skills and resources available in the Maris and Look laboratories. In Aim 1, we will focus on how polymorphisms at the LMO1 locus alter regulatory mechanisms of the LMO1 gene in developing sympathetic nervous system cells to promote the initiation of neuroblastoma using genetic and epigenetic approaches in human-derived tissues and genome editing in the zebrafish model system. In Aim 2, we will focus on the mechanism by which LMO1 overexpression is somatically deregulated during malignant neuroblastic clonal evolution, and will seek to discover the key cellular networks that maintain the highly proliferative and metastatic phenotype characteristic of neuroblastomas high levels of LMO1 expression. The innovation of this project resides in the combined use of robust human (epi)genetic approaches with a novel and highly manipulable zebrafish model of neuroblastoma to address a fundamental problem with high clinical relevance. Our results will establish the requirement for LMO1 in neuroblastoma initiation, growth and survival. The work proposed here will serve as a roadmap for the investigation of GWAS discoveries in cancer and other human diseases, providing a paradigm for determining their mechanistic and clinical relevance.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A. THOMAS LOOK其他文献
A. THOMAS LOOK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A. THOMAS LOOK', 18)}}的其他基金
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
癌症中异常转录增强子的机制和脆弱性
- 批准号:
9341186 - 财政年份:2016
- 资助金额:
$ 60.68万 - 项目类别:
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
癌症中异常转录增强子的机制和脆弱性
- 批准号:
10238895 - 财政年份:2016
- 资助金额:
$ 60.68万 - 项目类别:
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
癌症中异常转录增强子的机制和脆弱性
- 批准号:
10004576 - 财政年份:2016
- 资助金额:
$ 60.68万 - 项目类别:
Role of LMO1 in Neuroblastoma Initiation and Maintenance
LMO1 在神经母细胞瘤发生和维持中的作用
- 批准号:
9032459 - 财政年份:2015
- 资助金额:
$ 60.68万 - 项目类别:
Role of LMO1 in Neuroblastoma Initiation and Maintenance
LMO1 在神经母细胞瘤发生和维持中的作用
- 批准号:
9238724 - 财政年份:2015
- 资助金额:
$ 60.68万 - 项目类别:
Role of LMO1 in Neuroblastoma Initiation and Maintenance
LMO1 在神经母细胞瘤发生和维持中的作用
- 批准号:
8888225 - 财政年份:2015
- 资助金额:
$ 60.68万 - 项目类别:
Discovery of New Targets and Pathways for T-ALL Therapy
T-ALL 治疗新靶点和途径的发现
- 批准号:
8710114 - 财政年份:2012
- 资助金额:
$ 60.68万 - 项目类别:
Discovery of New Targets and Pathways for T-ALL Therapy
T-ALL 治疗新靶点和途径的发现
- 批准号:
8901763 - 财政年份:2012
- 资助金额:
$ 60.68万 - 项目类别:
Discovery of New Targets and Pathways for T-ALL Therapy
T-ALL 治疗新靶点和途径的发现
- 批准号:
8550035 - 财政年份:2012
- 资助金额:
$ 60.68万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 60.68万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 60.68万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 60.68万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 60.68万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 60.68万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 60.68万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 60.68万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 60.68万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 60.68万 - 项目类别: